Merck Lipfendra FDA Approval Expands Portfolio
Merck Lipfendra FDA approval adds the first oral PCSK9 pill to Merck's portfolio and a $315 list price could shape adoption and payer positioning.
KEY TAKEAWAYS
- FDA approved Lipfendra as the first once-daily oral PCSK9 inhibitor to reduce LDL-C.
- CORALreef Phase 3 trials showed placebo-adjusted LDL-C reductions of 56% and 59% at Week 24.
- An outcomes trial is ongoing and the approval does not include cardiovascular event claims.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Merck & Co. (MRK) won U.S. FDA approval for Lipfendra on July 16, 2026, authorizing the first once-daily oral PCSK9 pill to lower LDL cholesterol (LDL-C). The approval adds a cardiovascular therapy that broadens Merck’s portfolio beyond oncology.
FDA Approval and Trial Results
The FDA approved LIPFENDRA (enlicitide) tablets 20 mg as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). The agency granted Priority Review and listed Merck Sharp & Dohme LLC as the sponsor.
Approval was based on the CORALreef Phase 3 program, which enrolled 3,207 adults across two randomized, double-blind, placebo-controlled trials of patients already on maximally tolerated statin therapy. The larger CORALreef Lipids trial randomized 2,904 patients two-to-one for 52 weeks, while a separate 303-patient HeFH study produced placebo-adjusted LDL-C reductions of 56% and 59% at Week 24, respectively. Both trials met their primary endpoint of percent change in LDL-C from baseline and showed significant reductions in non-HDL cholesterol and apolipoprotein B.
Safety, Mechanism, and Market Outlook
Safety profiles in the pivotal trials were similar to placebo in the larger CORALreef Lipids study but showed higher rates of diarrhea and dizziness in the HeFH cohort. Diarrhea occurred in 7% of Lipfendra patients versus 2% on placebo, and dizziness in 9% versus 4%. Treatment discontinuation rates due to adverse reactions were comparable across groups.
Lipfendra is an oral PCSK9 inhibitor, a macrocyclic peptide that blocks PCSK9 binding to LDL receptors. It delivers PCSK9–LDL receptor blockade by mouth rather than by injectable monoclonal antibody, offering an oral alternative for patients needing additional cholesterol lowering beyond statins, which remain the standard oral therapy targeting cholesterol synthesis.
Financial reports list a $315 per 30-day supply list price for Lipfendra, below existing injectable PCSK9 therapies priced above $500 per month. Merck plans to offer a discounted cash price through the U.S. government’s TrumpRx.gov program.
An ongoing cardiovascular outcomes trial, CORALreef Outcomes (NCT06008756), is evaluating Lipfendra’s effects on cardiovascular morbidity and mortality. The FDA approval does not include claims of reduced cardiovascular events.
Analysts have noted the potential for multi-billion-dollar annual sales and a new revenue stream for Merck if uptake meets expectations, citing the ease of oral dosing and the lower list price as adoption drivers. These outlooks reflect analyst estimates, not company guidance.
“This is a pivotal moment as we bring the first U.S. FDA-approved oral PCSK9 inhibitor to adults with high LDL-C, offering patients an important new option,” said Merck’s executive vice president of global clinical development.
